AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

Psyence Biomedical has walked away from its planned acquisition of fellow Canadian psilocybin-based biotech Clairvoyant ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. | Big Pharma is investing heavily ...